Hospital Clínic-IDIBAPS is the only hospital in Europe to have fully developed two academic CAR T-cell therapies that have been approved by a regulat1
Girem Full! (Let's Turn the Page!) is a charity event that aims to raise funds for cancer immunotherapy research by promoting reading.
Researchers at IDIBAPS- Hospital Clínic have developed and validated a new CAR-T therapy called ARI0003 at a preclinical level. The new therapy combi1
A team from Clínic-IDIBAPS has introduced a modification to a CAR-T immunotherapy for multiple myeloma that makes it more durable, according to resul1
The Committee for the Evaluation of Medicinal Products for Human Use of the Spanish Agency of Medicines and Medical Devices (AEMPS) has approved ARI01
A study published recently in the journal Clinical Cancer Research identified biomarkers that can predict the response to CAR T-cell therapy targetin1
A study led by researchers from the Clínic-IDIBAPS paves the way for the design and optimization of CAR T-cell therapy for greater effectiveness in t1
An international team, co-led by the Hospital Clínic-IDIBAPS, has identified four biomarkers that determine the risk of the recurrence of this cancer1
A multicentre study led by the Hospital Clínic Barcelona-IDIBAPS demonstrates the efficacy of the CAR T-cell therapy ARI0002h in treating patients wi1
The University of Pennsylvania professor and pioneer in developing cancer therapies using T cells covered the history, current state, and future chal1
